From: Validation of the Toronto hepatocellular carcinoma risk index for patients with cirrhosis in China: a retrospective cohort study
THRI score
All patients (n = 520)
HCC (n = 76)
Non-HCC (n = 444)
< 120, n (%)
23 (4.4)
0 (0.0)
23 (5.2)
120–240, n (%)
248 (47.7)
20 (26.3)
228 (51.4)
> 240, n (%)
249 (47.9)
56 (73.7)
193 (43.5)